Sep 28, 2023 / 03:30PM GMT
Li Watsek - Cantor Fitzgerald, L.P. - Analyst
All right, guys, welcome to the fireside chat with Arvinas. I'm Li Watsek, a biotech analyst at Cantor. So I'm very pleased today to be joined by management team, Sean Cassidy, CFO; and Ron Peck, CMO. Great to have you both. I know most people are probably very familiar with the story, but I guess just to level set, maybe give us a quick overview update and what's coming up this year?
Questions and Answers:
Sean Cassidy - Arvinas, Inc. - CFOSure. So first, thanks for having us. We're the leader in targeted protein degradation. Our two lead clinical programs is vepdegestrant, which is a partnership with Pfizer, which is our estrogen receptor degrader, as well as two assets and our antigen receptor degrader program, which is for metastatic castration-resistant prostate cancer.
We have two data releases coming up, one at ESMO around bavdegalutamide, which Ron will cover in relative detail but really excited to get some PFS data out in the marketplace with respect to that program, and then also an
Trustpilot
